Reason for request

Reassessment of actual benefit and improvement in actual benefit under article R-163-21 of the Social Security Code.


Clinical Benefit


The actual benefit is moderate.

Clinical Added Value


The Transparency Committee is of the opinion that the REMODULIN range of proprietary drugs provides a minor improvement in actual benefit (IAB IV) in the treatment of idiopathic pulmonary arterial hypertension for patients in functional class III.

Contact Us

Évaluation des médicaments

See also